|
Regentis Biomaterials Ltd.
Core Business / Technology
Regentis has developed a state-of-the-art tissue regeneration substrate
called Gelrin™ with the participation of leading biomaterial scientists
and orthopedic surgeons. The company is focused on commercializing its
platform technology for the cartilage repair market. The ultimate aim of
Gelrin™ is restoration of normal knee function by regenerating hyaline
cartilage in the defect site, with complete integration of the
regenerated cartilage with the surrounding cartilage and underlying
bone.
The Gelrin™ technology is based on a biosynthetic hybrid hydrogel
comprised of a biological backbone and synthetic cross-links. The
biological domains in the material give Gelrin™ excellent healing
properties, while the synthetic cross-links provide the material
superior physical characteristics. The biodegradation of Gelrin™ is
fully controllable and enables precise regulation over the ingrowth
kinetics and healing properties. The ability to form Gelrin™ in-situ at
the site of the defect provides the possibility of using it with
minimally invasive surgical procedures. While other materials degrade
rapidly or leach out of the injury site prematurely, Gelrin™ remains
anchored during the entire healing process. This unique combination of
properties makes Gelrin™ highly distinctive in the orthopedic market.
Main Markets / Applications
Cartilage injury afflicts over one million patients annually in the U.S.
There are approximately 650,000 procedures each year to repair
cartilaginous injuries (not including 350,000 total knee replacement
procedures) and a majority of these procedures are repeat treatments,
showing the ineffectiveness of current therapeutic treatments. The
cartilage regeneration market annual potential in the U.S. and Europe is
400,000 procedures with a market value of $1.6B.
Uniqueness / Advantage over Existing Products
The Gelrin platform has several distinct competitive advantages
over other products in the bone and cartilage regeneration market,
including:
-Facilitation of cells attachment and regulation of cell phenotype:
-Control over material properties
-Control over biodegradation kinetics
-In-situ and ex-vivo formation and delivery
Management
• Yehiel Tal – CEO and Co-Founder
• Dr. Dror Seliktar – CSO and Co-Founder
• Eli Peled, M.D – Manager of Clinical Affairs
Seeking
Funding source, strategic partner
Website
www.regentis.co.il
|
|
